WO2005123137A2 - Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride - Google Patents

Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride

Info

Publication number
WO2005123137A2
WO2005123137A2 PCT/IB2005/001716 IB2005001716W WO2005123137A2 WO 2005123137 A2 WO2005123137 A2 WO 2005123137A2 IB 2005001716 W IB2005001716 W IB 2005001716W WO 2005123137 A2 WO2005123137 A2 WO 2005123137A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
solution
moxifloxacin
lyophilized
Prior art date
Application number
PCT/IB2005/001716
Other languages
French (fr)
Other versions
WO2005123137A3 (en
Inventor
Ashish Sehgal
Jyoti Srivastava
Vinod Kumar Arora
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2005123137A2 publication Critical patent/WO2005123137A2/en
Publication of WO2005123137A3 publication Critical patent/WO2005123137A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride.
  • Moxifloxacin is an antibiotic from the class of the quinolone carboxylic acids and is also named as l-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-l,4- dihydro-8-methoxy-4-oxo-3-quinolonecarboxylic acid. It is a highly effective anti-infective agent and was described for the first time in
  • EP 350,733 does not describe any pharmaceutical preparations which are suitable for parenteral administration. Such solutions for infusion, which can be administered parenterally are, however, needed for treating those patients in intensive care units who cannot be treated orally.
  • U.S. Patent No 6,548,079 describes a ready-to-use aqueous formulation comprising moxifloxacin hydrochloride (0.04% to 0.4% M/V) and sodium chloride (0.4% to 0.9% M/V) wherein the medicament is used for preventing or treating bacterial infections in humans and animals.
  • moxifloxacin has a problem of solubility and stability. The durg is poorly soluble in the presence of sodium chloride salt and is unstable in the presence of sugars or sugar alcohols, which are the most commonly used agents to make the parenteral products isotonic with the blood.
  • PCT Application No. WO 01/10408 relates to an aqueous formulation of a medicament comprising moxifloxacin or its salt and a sugar or sugar alcohol. It is characterized in that it contains less than 20 ppb of iron. Summary of the Invention
  • the present invention relates to a stable lyophilized pharmaceutical composition
  • a stable lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride as an active drug substance and the use of said preparation for preventing or treating bacterial infections in humans or animals.
  • the lyophilized compositions of the invention are characterized by comprising, in addition to the active drug substance, one or more solubilizing agents that are able to enhance the solubility of moxifloxacin hydrochloride.
  • the object of present invention is to provide a stable lyophilized pharmaceutical composition for parenteral administration comprising moxifloxacin hydrochloride and a process of its preparation.
  • a stable lyophilized pharmaceutical composition for parenteral administration comprising moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
  • Embodiments of the pharmaceutical composition may include one o rmore of the following features.
  • the parenteral administration may include intravenous, intra-arterial, subcutaneous, intramuscular and intraperitoneal administration.
  • the solubilizing agent may be one or more of L-arginine, histidine or lysine.
  • the moxifloxacin and solubilizing agent are present in the range of 1 :0.1 to 1 : 10.
  • the composition may further include excipients selected from one or more of bulking agents, buffers, antioxidants, chelating agents, cryoprotectants and lyoprotectants.
  • the composition may include about 400 mg of moxifloxacin hydrochloride and may include about 112.5 mg of L-arginine.
  • the pharmaceutical composition may have less than or equal to 0.16% of related substances after storage for three months at 40°C and 75% relative humidity.
  • the lyophilized composition is reconstituted shortly before use. Reconstitution may include using a sterile physiological solution.
  • the sterile physiological solution may be selected from one or more of sodium lactate solution and sodium bicarbonate solution.
  • the pH of the reconstituted solution remains constant for up to one hour storage at room temperature after reconstitution.
  • the reconstituted solution may have moxifloxacin hydrochloride being present at from 0.04% to 3% w/v. •
  • a process for preparing a lyophilized pharmaceutical composition for parenteral administration that includes moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
  • the process includes the steps of: dissolving moxifloxacin and one or more solubilizing agents in a solvent, filtering to eliminate the bacteria, subpackaging into sterile containers, lyophilizing, and drying.
  • Embodiments of the process may include one or more of the following features.
  • the solvent may include water for injection.
  • the process may further include reconstituting the lyophilized product.
  • a method for preventing or treating bacterial infections in human or animals includes administering to the human or animal a stable lyophilized pharmaceutical composition that includes moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
  • Embodiments of the method of use may include one or moreof the following features or those described above.
  • the solubilizing agent may be one or more of L-arginine, histidine or lysine.
  • the lyophilized composition may be reconstituted shortly before use by using a sterile physiological solution selected from one or more of sodium lactate solution and sodium bicarbonate solution. The pH of the reconstituted solution may remain constant for up to one hour storage at room temperature after reconstitution.
  • Lyophihzation or freeze drying is a process in which water is removed from a product by freezing the product and placing it under a vacuum, which allows the ice to change directly from the solid phase to the vapor phase without passing through the liquid phase.
  • the process consists of three separate, unique, and interdependent processes: freezing, primary drying (sublimation), and secondary drying (desorption).
  • freezing primary drying
  • secondary drying desorption
  • the lyophihzation process generally includes the following steps:
  • a suitable solvent generally water for injection (WFI).
  • lyophilized refers to a freeze-dried powder composition comprising moxifloxacin hydrochloride and a solubilizing agent.
  • physiologic solutions refer to various injectable solutions that can be used for reconstitution in order to obtain isotonic solutions, i.e., a solution having a tonicity comparable to that of blood.
  • the solutions may be, for example, selected from sodium lactate solution, sodium bicarbonate solution and the like.
  • the solubilizing agent as used herein refers to a substance that is able to enhance the solubility of the lyophilized cake on reconstitution with physiological solutions.
  • the solubilizing agent may be selected from L-arginine, histidine, and lysine.
  • the ratio of moxifloxacin to solubilizing agent is in the range of 1 :0.1 to 1 : 10, and more particularly it can be in the range of 1 :0.2 to 1:1.
  • the composition may comprise other excipients.
  • Excipients are used in lyophihzation primarily to provide a stable liquid environment for the active ingredient for some finite time.
  • the excipient may also cryoprotect, or otherwise protect, the active ingredient during the freezing process.
  • the excipient may also serve only as a bulking agent. The addition of bulking agents such as mannitol and dextran strengthen cake structure.
  • formulations for lyopliilization are totally aqueous solutions, although others contain solvents, such as tertiary butyl alcohol, to increase the solubility of some compounds.
  • excipients examples include buffers, antioxidants, chelating agents, cryoprotectants and lyoprotectants.
  • buffers suitable for lyophihzation include Tris, citrate, and histidine buffers.
  • lyoprotectants include sugars, PEG and certain inorganic salts.
  • cryoprotectants include sugars such as lactose, trehalose, and sucrose; and polymers such as polyvinyl-pyrrolidone and PEG.
  • the production process for making lyophilized powder includes the steps of aseptic filtration of a solution of moxifloxacin hydrochloride and arginine in water for injection. Specific amounts of this solution are placed in 30 ml capacity vials, which are then plugged partially with a slotted rubber plug. These vials are then placed in a lyophilizer. The vials, which have the solution in an aqueous phase are then subjected to a very cold temperature, which causes the water to freeze into ice. The ice is then removed by a process called sublimation; during this process, the frozen mixture is subjected to an intense vacuum.
  • the dry powder so obtained can be reconstituted with physiological solutions to result in solutions that have known stability periods. For example, a first dilution is done with a small amount of physiologic solution, which remains stable for 30 min at room temperature, and then this solution is subject to a second, further dilution up to 250ml with physiologic solution. This solution remains stable for 2 hours at room temperature and 24 hrs at 2-8°C.
  • moxifloxacin hydrochloride and L-arginine are dissolved in water for injection and then aseptically filtered. A specific amount of this solution is placed in a vial of 30 ml capacity and lyophilized leaving behind the dry powder in the form of cake containing moxifloxacin hydrochloride and L-arginine. The lyophilized powder so formed can be reconstituted in sodium lactate before use.
  • the reconstituted solution comprises moxifloxacin hydrochloride from 0.04% to 3% w/v, in particular from 0.1% to 0.2% w/v, and most particularly about 0.16% w/v of moxifloxacin hydrochloride, corresponding to 400 mg of moxifloxacin hydrochloride in 250 ml of physiologic solution.
  • the lyophilized injectable preparations serve as a medicament for parenteral administration, in particular as a medicament for preventing and treating bacterial infections.
  • Parenteral administration includes, for example, intravenous, intra-arterial, subcutaneous, intramuscular and intraperitoneal administration.
  • a dose, which is considered to be suitable, is 400 mg of active compound for intravenous infusion once per day.
  • the daily infusion volume administered should not exceed 200 to 250 ml.
  • the amount of active compound is 400 mg in the lyophilized cake, after reconstitution with physiologic solutions this results in an active compound concentration of about 0.16% (w/v), corresponding to 400 mg of moxifloxacin hydrochloride in 250 ml of physiologic solution.
  • the lyophilized pharmaceutical composition when reconstituted with physiologic solutions at final concentration may be stored for up to 2 hours at controlled room temperature 15-25°C and for up to 24 hours at 4°C.
  • Moxifloxacin hydrochloride and L-arginine are dissolved in water for injection, which is then aseptically filtered through a 0.2 micron filter.
  • step 3 The vials of step 2 are then placed in a lyophilizer.
  • Example 1 All the steps as well as the composition were the same as Example 1 except at step 6 where 5% sodium bicarbonate injection was used for reconstitution.
  • the composition of Example 1 was subjected to stability studies both in dry form as well as reconstituted form. The results of these studies are provided in Tables 1-3.
  • the reconstituted products of Examples 2 and 3 were also subjected to stability studies. The results for these studies are provided in Tables 2 and 3.
  • the colour of the lyophilized powder and reconstituted solution was yellow, and no change in colour was observed during the entire stability study. In addition, there was no particulate matter observed in the reconstituted solutions during and at the end of stability study.
  • a - sodium lactate indicates sodium lactate injection USP; — sodium bicarbonate indicates sodium bicarbonate injection; # 2hr/RT for Sodium Lactate and 1 hr RT for Sodium Bicarbonate $ 4hr/2-8°C for Sodium Bicarbonate & 24hr/4°C for Sodium Lactate
  • Lyophilized powder was stable for 3 months at 45°C at 75% RH as given in Table 1. No substantial change in pH was observed when the reconstituted solution was subjected to the various conditions as reported in Table 2. Thus, as used herein, Table 2 shows that the pH of the reconstituted solutions remain constant for up to one hour storage at room temperature after reconstitution. In addition, the reconstituted solution (both sodium lactate as well as sodium bicarbonate) was also stable at 45°C at 75% RH for 3 months as reported in Table 3. While several particular forms of the inventions have been described, it will be apparent that various modifications and combinations of the inventions detailed in the text can be made without departing from the spirit and scope of the inventions. Accordingly, it is not intended that the inventions be limited, except as by the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to stable lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride as an active drug substance and the use of the preparation for preventing or treating bacterial infections in humans or animals.

Description

LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING MOXIFLOXACIN HYDROCHLORIDE
Field of the Invention
The present invention relates to a lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride.
Background of the Invention
Moxifloxacin is an antibiotic from the class of the quinolone carboxylic acids and is also named as l-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-l,4- dihydro-8-methoxy-4-oxo-3-quinolonecarboxylic acid. It is a highly effective anti-infective agent and was described for the first time in
EP 350,733. However, EP 350,733 does not describe any pharmaceutical preparations which are suitable for parenteral administration. Such solutions for infusion, which can be administered parenterally are, however, needed for treating those patients in intensive care units who cannot be treated orally. U.S. Patent No 6,548,079 describes a ready-to-use aqueous formulation comprising moxifloxacin hydrochloride (0.04% to 0.4% M/V) and sodium chloride (0.4% to 0.9% M/V) wherein the medicament is used for preventing or treating bacterial infections in humans and animals. The patent also mentions that moxifloxacin has a problem of solubility and stability. The durg is poorly soluble in the presence of sodium chloride salt and is unstable in the presence of sugars or sugar alcohols, which are the most commonly used agents to make the parenteral products isotonic with the blood.
PCT Application No. WO 01/10408 relates to an aqueous formulation of a medicament comprising moxifloxacin or its salt and a sugar or sugar alcohol. It is characterized in that it contains less than 20 ppb of iron. Summary of the Invention
The present invention relates to a stable lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride as an active drug substance and the use of said preparation for preventing or treating bacterial infections in humans or animals. The lyophilized compositions of the invention are characterized by comprising, in addition to the active drug substance, one or more solubilizing agents that are able to enhance the solubility of moxifloxacin hydrochloride.
Thus, the object of present invention is to provide a stable lyophilized pharmaceutical composition for parenteral administration comprising moxifloxacin hydrochloride and a process of its preparation.
Hence, in one aspect there is provided a stable lyophilized pharmaceutical composition for parenteral administration comprising moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
Embodiments of the pharmaceutical composition may include one o rmore of the following features. For example, the parenteral administration may include intravenous, intra-arterial, subcutaneous, intramuscular and intraperitoneal administration.
The solubilizing agent may be one or more of L-arginine, histidine or lysine. The moxifloxacin and solubilizing agent are present in the range of 1 :0.1 to 1 : 10. The composition may further include excipients selected from one or more of bulking agents, buffers, antioxidants, chelating agents, cryoprotectants and lyoprotectants.
In various embodiments, the composition may include about 400 mg of moxifloxacin hydrochloride and may include about 112.5 mg of L-arginine.
The pharmaceutical composition may have less than or equal to 0.16% of related substances after storage for three months at 40°C and 75% relative humidity. The lyophilized composition is reconstituted shortly before use. Reconstitution may include using a sterile physiological solution. The sterile physiological solution may be selected from one or more of sodium lactate solution and sodium bicarbonate solution. The pH of the reconstituted solution remains constant for up to one hour storage at room temperature after reconstitution. The reconstituted solution may have moxifloxacin hydrochloride being present at from 0.04% to 3% w/v. • In another general aspect there is provided a process for preparing a lyophilized pharmaceutical composition for parenteral administration that includes moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents. The process includes the steps of: dissolving moxifloxacin and one or more solubilizing agents in a solvent, filtering to eliminate the bacteria, subpackaging into sterile containers, lyophilizing, and drying.
Embodiments of the process may include one or more of the following features. For example, the solvent may include water for injection. The process may further include reconstituting the lyophilized product.
In another general aspect there is provided a method for preventing or treating bacterial infections in human or animals. The method includes administering to the human or animal a stable lyophilized pharmaceutical composition that includes moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
Embodiments of the method of use may include one or moreof the following features or those described above. For example, the solubilizing agent may be one or more of L-arginine, histidine or lysine. The lyophilized composition may be reconstituted shortly before use by using a sterile physiological solution selected from one or more of sodium lactate solution and sodium bicarbonate solution. The pH of the reconstituted solution may remain constant for up to one hour storage at room temperature after reconstitution.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. Detailed Description of the Invention
Lyophihzation or freeze drying is a process in which water is removed from a product by freezing the product and placing it under a vacuum, which allows the ice to change directly from the solid phase to the vapor phase without passing through the liquid phase. The process consists of three separate, unique, and interdependent processes: freezing, primary drying (sublimation), and secondary drying (desorption). There are several advantages associated with lyophihzation, such as: (i) ease of processing a liquid, which simplifies aseptic handling; (ii) enhanced stability of a dry powder; (iii) removal of water without excessive heating of the product; (iv) enhanced product stability in a dry state; and (v) rapid and easy dissolution of the reconstituted product.
The lyophihzation process generally includes the following steps:
- Dissolving the drug and excipients in a suitable solvent, generally water for injection (WFI).
- Sterilizing the bulk solution by passing it through a 0.22 micron bacteria-retentive filter.
- Filling into individual sterile containers and partially stoppering the containers under aseptic conditions.
- Transporting the partially stoppered containers to the lyophilizer and loading into the chamber under aseptic conditions. - Freezing the solution by placing the partially stoppered containers on cooled shelves in a freeze-drying chamber or pre-freezing in another chamber.
- Applying a vacuum to the chamber and heating the shelves in order to evaporate the water from the frozen state.
- Complete stoppering of the vials usually by hydraulic or screw rod stoppering mechanisms installed in the lyophilizers. The term lyophilized as used herein refers to a freeze-dried powder composition comprising moxifloxacin hydrochloride and a solubilizing agent.
The term physiologic solutions as used herein refer to various injectable solutions that can be used for reconstitution in order to obtain isotonic solutions, i.e., a solution having a tonicity comparable to that of blood. The solutions may be, for example, selected from sodium lactate solution, sodium bicarbonate solution and the like.
The solubilizing agent as used herein refers to a substance that is able to enhance the solubility of the lyophilized cake on reconstitution with physiological solutions. The solubilizing agent may be selected from L-arginine, histidine, and lysine. The ratio of moxifloxacin to solubilizing agent is in the range of 1 :0.1 to 1 : 10, and more particularly it can be in the range of 1 :0.2 to 1:1.
In addition to one or more solubilizing agents, the composition may comprise other excipients. Excipients are used in lyophihzation primarily to provide a stable liquid environment for the active ingredient for some finite time. The excipient may also cryoprotect, or otherwise protect, the active ingredient during the freezing process. The excipient may also serve only as a bulking agent. The addition of bulking agents such as mannitol and dextran strengthen cake structure.
Most formulations for lyopliilization are totally aqueous solutions, although others contain solvents, such as tertiary butyl alcohol, to increase the solubility of some compounds.
Examples of other excipients include buffers, antioxidants, chelating agents, cryoprotectants and lyoprotectants. Examples of buffers suitable for lyophihzation include Tris, citrate, and histidine buffers. Example of lyoprotectants include sugars, PEG and certain inorganic salts. Examples of cryoprotectants include sugars such as lactose, trehalose, and sucrose; and polymers such as polyvinyl-pyrrolidone and PEG.
The production process for making lyophilized powder includes the steps of aseptic filtration of a solution of moxifloxacin hydrochloride and arginine in water for injection. Specific amounts of this solution are placed in 30 ml capacity vials, which are then plugged partially with a slotted rubber plug. These vials are then placed in a lyophilizer. The vials, which have the solution in an aqueous phase are then subjected to a very cold temperature, which causes the water to freeze into ice. The ice is then removed by a process called sublimation; during this process, the frozen mixture is subjected to an intense vacuum. Since ice has a low but significant level of "vapor pressure", the vacuum gradually pulls the molecules of water out of and away from the ice, and removes them. The intense vacuum inside a lyophihzation chamber can thereby remove the water from the solution, leaving behind the dry powder containing moxifloxacin hydrochloride and L- arginine.
The dry powder so obtained can be reconstituted with physiological solutions to result in solutions that have known stability periods. For example, a first dilution is done with a small amount of physiologic solution, which remains stable for 30 min at room temperature, and then this solution is subject to a second, further dilution up to 250ml with physiologic solution. This solution remains stable for 2 hours at room temperature and 24 hrs at 2-8°C.
In one of the embodiments moxifloxacin hydrochloride and L-arginine are dissolved in water for injection and then aseptically filtered. A specific amount of this solution is placed in a vial of 30 ml capacity and lyophilized leaving behind the dry powder in the form of cake containing moxifloxacin hydrochloride and L-arginine. The lyophilized powder so formed can be reconstituted in sodium lactate before use.
The reconstituted solution comprises moxifloxacin hydrochloride from 0.04% to 3% w/v, in particular from 0.1% to 0.2% w/v, and most particularly about 0.16% w/v of moxifloxacin hydrochloride, corresponding to 400 mg of moxifloxacin hydrochloride in 250 ml of physiologic solution.
The lyophilized injectable preparations serve as a medicament for parenteral administration, in particular as a medicament for preventing and treating bacterial infections. Parenteral administration includes, for example, intravenous, intra-arterial, subcutaneous, intramuscular and intraperitoneal administration. A dose, which is considered to be suitable, is 400 mg of active compound for intravenous infusion once per day. The daily infusion volume administered should not exceed 200 to 250 ml. As the amount of active compound is 400 mg in the lyophilized cake, after reconstitution with physiologic solutions this results in an active compound concentration of about 0.16% (w/v), corresponding to 400 mg of moxifloxacin hydrochloride in 250 ml of physiologic solution.
The lyophilized pharmaceutical composition when reconstituted with physiologic solutions at final concentration may be stored for up to 2 hours at controlled room temperature 15-25°C and for up to 24 hours at 4°C.
The following examples are illustrative of the invention, and are not to be construed as limiting the invention.
EXAMPLE 1
Figure imgf000008_0001
1. Moxifloxacin hydrochloride and L-arginine are dissolved in water for injection, which is then aseptically filtered through a 0.2 micron filter.
2. 5.7 ml of this solution is filled in vials of 30 ml capacity, which are then plugged partially with a slotted rubber plug.
3. The vials of step 2 are then placed in a lyophilizer.
4. The vials in the lyophilizer, which contain the solution in an aqueous phase, are then subjected to a very cold temperature, causing the water to freeze into ice.
5. The ice is then removed by subjecting the frozen mixture to an intense vacuum and by slowly elevating the temperature. 6. Lyophilized dry powder containing moxifloxacin hydrochloride and L-arginine is reconstituted with 13.3 ml of sodium lactate injection USP and further diluted up to 250 ml with sodium lactate injection USP before use.
EXAMPLE 2 All the steps as well as the composition were the same as Example 1 except at step 6 where 2.5 % sodium bicarbonate injection was used for reconstitution.
EXAMPLE 3
All the steps as well as the composition were the same as Example 1 except at step 6 where 5% sodium bicarbonate injection was used for reconstitution. The composition of Example 1 was subjected to stability studies both in dry form as well as reconstituted form. The results of these studies are provided in Tables 1-3. The reconstituted products of Examples 2 and 3 were also subjected to stability studies. The results for these studies are provided in Tables 2 and 3. The colour of the lyophilized powder and reconstituted solution was yellow, and no change in colour was observed during the entire stability study. In addition, there was no particulate matter observed in the reconstituted solutions during and at the end of stability study.
Table 1 : Stability study of moxifloxacin composition in dry form
Figure imgf000009_0001
Table 2: Change in pH of the constituted solution under different conditions
Figure imgf000010_0001
a- sodium lactate indicates sodium lactate injection USP; — sodium bicarbonate indicates sodium bicarbonate injection; # 2hr/RT for Sodium Lactate and 1 hr RT for Sodium Bicarbonate $ 4hr/2-8°C for Sodium Bicarbonate & 24hr/4°C for Sodium Lactate
Table 3: Stability study of moxifloxacin composition in reconstituted form
Figure imgf000011_0001
l- sodium lactate indicates sodium lactate injection USP; 5- sodium bicarbonate indicates sodium bicarbonate injection;
Lyophilized powder was stable for 3 months at 45°C at 75% RH as given in Table 1. No substantial change in pH was observed when the reconstituted solution was subjected to the various conditions as reported in Table 2. Thus, as used herein, Table 2 shows that the pH of the reconstituted solutions remain constant for up to one hour storage at room temperature after reconstitution. In addition, the reconstituted solution (both sodium lactate as well as sodium bicarbonate) was also stable at 45°C at 75% RH for 3 months as reported in Table 3. While several particular forms of the inventions have been described, it will be apparent that various modifications and combinations of the inventions detailed in the text can be made without departing from the spirit and scope of the inventions. Accordingly, it is not intended that the inventions be limited, except as by the appended claims.

Claims

We claim:
1. A lyophilized pharmaceutical composition for parenteral administration comprising moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
2. The pharmaceutical composition according to claim 1 wherein the parenteral administration includes intravenous, intra-arterial, subcutaneous, intramuscular and intraperitoneal administration.
3. The pharmaceutical composition according to claim 1 wherein the solubilizing agent comprises one or more of L-arginine, histidine or lysine.
4. The pharmaceutical composition according to claim 1 wherein the moxifloxacin and solubilizing agent are present in the range of 1 :0.1 to 1 : 10.
5. The pharmaceutical composition according to claim 1 wherein the lyophilized composition is reconstituted shortly before use.
6. The pharmaceutical composition according to claim 5 wherein reconstitution comprises using a sterile physiological solution.
7. The pharmaceutical composition according to claim 6 wherein the sterile physiological solution is selected from one or more of sodium lactate solution and sodium bicarbonate solution.
8. The pharmaceutical composition according to claim 7 wherein the pH of the reconstituted solution remains constant for up to one hour storage at room temperature after reconstitution.
9. The pharmaceutical composition according to claim 7 wherein the reconstituted solution comprises moxifloxacin hydrochloride being present at from 0.04% to 3% w/v.
10. The pharmaceutical composition according to claim 1 wherein the composition further comprises excipients selected from one or more of bulking agents, buffers, antioxidants, chelating agents, cryoprotectants and lyoprotectants.
11. The pharmaceutical composition according to claim 1 wherein the composition comprises about 400 mg of moxifloxacin hydrochloride.
12. The pharmaceutical composition according to claim 1 wherein the composition comprises about 112.5 mg of L-arginine.
13. The pharmaceutical composition according to claim 1 wherein the composition has less than or equal to 0.16% of related substances after storage for three months at 40°C and 75% relative humidity.
14. A process for preparation of a lyophilized pharmaceutical composition comprising moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents, the process comprising the steps of: dissolving moxifloxacin and one or more solubilizing agents in a solvent; filtering to eliminate any bacteria or other contaminants; subpackaging into sterile containers; lyophilizing; and drying.
15. The process according to claim 14 wherein the solvent comprises water for injection.
16. The process according to claim 14 further comprising reconstituting the lyophilized product.
17. The process according to claim 14 wherein the solubilizing agent comprises one or more of L-arginine, histidine or lysine.
18. A method for preventing or treating bacterial infections in a human or an animal comprising administering to the human or animal a stable lyophilized pharmaceutical composition comprising moxifloxacin or pharmaceutically acceptable salts thereof and one or more solubilizing agents.
19. The method of claim 18 wherein the solubilizing agent comprises one or more of L-arginine, histidine or lysine.
20. The method of claim 18 further comprising reconstituting the lyophilized composition shortly before use in a physiological solution selected from one or more of sodium lactate solution and sodium bicarbonate solution, wherein the pH of the reconstituted solution remains constant for up to one hour storage at room temperature after reconstitution.
PCT/IB2005/001716 2004-06-18 2005-06-17 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride WO2005123137A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1150/DEL/2004 2004-06-18
IN1150DE2004 2004-06-18

Publications (2)

Publication Number Publication Date
WO2005123137A2 true WO2005123137A2 (en) 2005-12-29
WO2005123137A3 WO2005123137A3 (en) 2006-03-30

Family

ID=34977105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001716 WO2005123137A2 (en) 2004-06-18 2005-06-17 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride

Country Status (1)

Country Link
WO (1) WO2005123137A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097003A1 (en) * 2011-12-26 2013-07-04 Ems S/A. Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method for the production thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537761A1 (en) * 1985-10-24 1987-04-30 Bayer Ag INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUOR-1,4-DIHYDRO-4-OXO-7- (1-PIPERAZINYL) -QUINOLINE-3-CARBONIC ACID
DE19937115A1 (en) * 1999-08-06 2001-02-08 Bayer Ag Aqueous drug formulation of moxifloxacin or salts thereof
FR2846304B1 (en) * 2002-10-28 2006-03-03 Valois Sas FLUID PRODUCT DISPENSING DEVICE FIXING ELEMENT AND FLUID PRODUCT DISPENSING DEVICE COMPRISING SUCH A FIXING ELEMENT

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097003A1 (en) * 2011-12-26 2013-07-04 Ems S/A. Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method for the production thereof

Also Published As

Publication number Publication date
WO2005123137A3 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
AU2004229407B2 (en) Compositions containing piperacillin and tazobactam useful for injection
US6900184B2 (en) Compositions containing pipercillin and tazobactam useful for injection
KR101638301B1 (en) Lyophilized cake formulations
MX2013003045A (en) Caspofungin composition.
CN102755296A (en) Sterile lyophilized preparation containing fosaprepitant, and preparation method thereof
JP2012167132A (en) FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXY BENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE
EA034565B1 (en) Compositions of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
CN101647774B (en) A kind of asarone injection and preparation method thereof
US20120283304A1 (en) Formulations of Temozolomide for Parenteral Administration
JP2002508330A (en) Pharmaceutical compositions and preparations based on dalfopristin and quinupristin
JP4617303B2 (en) Flupirtine pharmaceutical form for injection
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
SK284311B6 (en) Stabilised pharmaceutical compositions, with quinupristine and dalfopristine base and their preparation
AU2021227095B2 (en) Daptomycin formulation
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
CA2563665A1 (en) Method of stabilizing disordered cefovecin sodium salt
WO2022169582A1 (en) Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents
US20080096947A1 (en) Parenteral Forms Of Administration Of Imexon And Method For The Production Thereof
HK40033919A (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK40033919B (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK1069775B (en) Compositions containing piperacillin and tazobactam useful for injection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 7787/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase